Could intensified treatment in childhood acute lymphoblastic leukemia improve outcome independently of risk factors?

European Journal of Haematology

Volumn 75, Issue 5, 2005, Pages 361-369

  Tzortzatou Stathopoulou, Fotini ^a   Moschovi, Maria A ^a   Papadopoulou, Athina L ^a   Barbounaki, Ioanna G ^a   Lambrou, George I ^a   Balafouta, Myrsini ^a   Syriopoulou, Vassiliki ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute lymphoblastic leukemia; Childhood; Intensified protocol; Outcome; Risk factors

Indexed keywords

ASPARAGINASE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; TIOGUANINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CANCER THERAPY; CHILD; CHILDHOOD LEUKEMIA; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CLINICAL PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; MALE; RECURRENCE; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 26844562426     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00527.x     Document Type: Article

References (33)

1. GAYNON PS, DESAI AA, BOSTROM BC, et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997;80:1717-1726.
2. PUI CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000;12:3-12.
3. RAVINDRANATH Y. Recent advances in pediatric acute lymphoblastic and myeloid leukemia. Curr Opin Oncol 2003;15:23-35.
4. SANDLUND JT, HARRISON PL, RIVERA G, et al. Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia. Blood 2002;100:43-47.
5. SCHRAPPE M. Evolution of BFM trials for childhood ALL. Ann Hematol 2004;83(Suppl. 1):S121-S123.
6. PUI CH, SANDLUND JT, PEI D, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Total Therapy Study XIIIB at St. Jude Children's Research Hospital. Blood 2004;104:2690-2696.
7. SCHRAPPE M, REITER A, ZIMMERMANN M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000;14:2205-2222.
8. SCHRAPPE M, REITER A, LUDWIG WD, et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. Blood 2000;95:3310-3322.
9. CHESSELLS JM, HARRISON G, RICHARDS SM, et al. Medical Research Council Working Party On Childhood Leukaemia. Failure of a new protocol to improve treatment results in paediatric lymphoblastic leukaemia: lessons from the UK Medical Research Council trials UKALL X and UKALL XI. Br J Haematol 2002;118:445-455.
10. GAYNON PS, TRIGG ME, HEEREMA NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000;14:2223-2233.
11. SILVERMAN LB, GELBER RD, DALTON VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-1218.
12. TOYODA Y, MANABE A, TSUCHIDA M, et al. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood. J Clin Oncol 2000;18:1508-1516.
13. STEINHERZ PG, REDNER A, STEINHERZ L, et al. Development of a new intensive therapy for acute lymphoblastic leukemia in children at increased risk of early relapse: The Memorial Sloan-Kettering-New York-II Protocol. Cancer 1993;72:3120-3130.
14. TZORTZATOU-STATHOPOULOU F, PAPADOPOULOU A, MOSCHOVI M, et al. Low Relapse rate in children with acute lymphoblastic leukaemia after risk-directed therapy. J Ped Hematol Oncol 2001;23:591-597.
15. REITER A, SCHRAPPE M, TIEMANN M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994;12:899-908.
16. SEIDEMANN K, TIEMANN M, SCHRAPPE M, et al. Short-pulse B-non-Hodgkin lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt-Munster group trial NHL-BFM 90. Blood 2001;97:3699-3706.
17. MOSCHOVI M, THEODORIDOU M, PAPAEVANGELOU V, et al. Outbreak of Enteroviral infection in a Pediatric Hematology-Oncology Unit. Clin Infect Dis 2002;34:1269-1272.
18. REITER A, SCHRAPPE M, LUDWIG WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-3133.
19. LANGE BJ, BOSTROM BC, CHERLOW JM, et al. Children's Cancer Group.Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 2002;99:825-833.
20. VILMER E, SUCIU S, FERSTER A, et al. Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group. Leukemia 2000;14:2257-2266.
21. KAMPS WA, BOKKERINK JP, HAKVOORT-CAMMEL FG, et al. BFM-oriented treatment for children with acute lymphoblastic leukemia without cranial irradiation and treatment reduction for standard risk patients: results of DCLSG protocol ALL-8 (1991-1996). Leukemia 2002;16:1099-1111.
22. GOLDIE JH, COLDMAN AJ. The genetic origin of drug resistance in neoplasms: imlications for systemic therapy. Cancer Res 1984;44:3643-3653.
23. HOLLEMAN A, CHEOK MH, DEN BOER ML, et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med 2004;351:533-542.
24. PUI CH, BOYETT JM, RIVERA GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000;14:2286-2294.
25. CHESSELLS JM, BAILEY C, RICHARDS SM. Intensification of treatment and survival in all children with lymphoblastic leukemia: results of UK Medical Research Council trial UKALL X. Medical Research Council Working Party on Childhood Leukaemia. Lancet 1995;345:143-148.
26. SCHORIN MA, BLATTNER S, GELBER RD, et al. Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994;12:740-747.
27. PAPADOPOULOU A, THEODORIDOU M, SYRIOPOULOU V, MOSTROU G, KATTAMIS CH. Hepatitis in children hospitalized with measles: the experience acquired after a Greek epidemic. J Paediatr Child Health 2001;37:55-57.
28. BO J, SCHRODER H, KRISTINSSON J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999;86:1080-1086.
29. CLARKE M, GAYNON P, HANN I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol 2003;21:1798-1809.
30. SAARINEN-PIHKALA UM, GUSTAFSSON G, CARLSEN N, et al. Outcome of children with high-risk acute lymphoblastic leukemia (HR-ALL): Nordic results on an intensive regimen with restricted central nervous system irradiation. Pediatr Blood Cancer 2004;42:8-23.
31. WABER DP, SHAPIRO BL, CARPENTIERI SC, et al. Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia: a 7-year follow-up study of the Dana-Farber Cancer Institute Consortium Protocol 87-01. Cancer 2001;92:15-22.
32. PASTORE G, VISCOMI S, GEROV GL, et al. Population-based survival after childhood lymphoblastic leukemia in time periods corresponding to specific clinical trials- a report from the Childhood Cancer Registry of Piedmont (Italy). Eur J Cancer 2003;39:952-960.
33. ARICO M, VALSECCHI MG, CONTER V, et al. Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II. Blood 2002;100:420-426.